Literature DB >> 16919834

Induction of atopic eczema/dermatitis syndrome-like skin lesions by repeated topical application of a crude extract of Dermatophagoides pteronyssinus in NC/Nga mice.

Jong Soon Kang1, Kiho Lee, Sang-Bae Han, Ji-Mi Ahn, Hyunju Lee, Mi Hwa Han, Yeo Dae Yoon, Won Kee Yoon, Song-Kyu Park, Hwan Mook Kim.   

Abstract

Mite antigen has been considered to play important roles in the development of atopic eczema/dermatitis syndrome (AEDS). In the present study, we attempted to induce an AEDS-like skin lesion in mice using Dermatophagoides pteronyssinus crude extract (DPE) as an antigen and performed pathophysiological evaluations. Ears of mice were tape-stripped and DPE was painted 3 times a week. Eczematous skin lesion and ear swelling were apparent in NC/Nga mice treated with DPE after 2 weeks, whereas neither skin lesion nor ear swelling were observed in BALB/c mice even after 30 days. Histological evaluation demonstrated that edema, epidermal hyperplasia and the accumulation of inflammatory cells were apparent in the ears of DPE-treated NC/Nga mice. In contrast to skin lesion and ear swelling, total serum IgE levels were increased in both NC/Nga and BALB/c mice. Treatment with DPE also increased auricular lymph node weight in both NC/Nga mice and BALB/c mice. To further characterize, we analyzed cytokine mRNA expression in ears and lymph nodes of DPE-treated NC/Nga mice. Increased expression of IL-4 and TNF-alpha mRNA was observed in both ears and lymph nodes of NC/Nga mice treated with DPE. Additionally, there was no change in the responsiveness of BALB/c mice to DPE treatment by adaptive transfer of serum from DPE-treated NC/Nga mice to BALB/c mice. Taken together, our results indicate that eczematous skin lesion and ear swelling caused by repeated application of DPE in NC/Nga mice has a Th2-dominant background and that inflammation is involved in this process. The animal model of AEDS established in this report may be used to investigate the pathogenesis of AEDS and evaluate the potential therapeutic agents for AEDS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16919834     DOI: 10.1016/j.intimp.2006.06.011

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  6 in total

1.  Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges.

Authors:  Mao-Qiang Man; Yutaka Hatano; Seung H Lee; Mona Man; Sandra Chang; Kenneth R Feingold; Donald Y M Leung; Walter Holleran; Yoshikazu Uchida; Peter M Elias
Journal:  J Invest Dermatol       Date:  2007-08-02       Impact factor: 8.551

2.  Analysis of MAST-CLA Results as a Diagnostic Tool in Allergic Skin Diseases.

Authors:  Jung Won Shin; Seon-Pil Jin; Jong Hee Lee; Soyun Cho
Journal:  Ann Dermatol       Date:  2010-02-28       Impact factor: 1.444

3.  Flaky tail mouse denotes human atopic dermatitis in the steady state and by topical application with Dermatophagoides pteronyssinus extract.

Authors:  Catharina Sagita Moniaga; Gyohei Egawa; Hiroshi Kawasaki; Mariko Hara-Chikuma; Tetsuya Honda; Hideaki Tanizaki; Saeko Nakajima; Atsushi Otsuka; Hiroyuki Matsuoka; Akiharu Kubo; Jun-ichi Sakabe; Yoshiki Tokura; Yoshiki Miyachi; Masayuki Amagai; Kenji Kabashima
Journal:  Am J Pathol       Date:  2010-03-19       Impact factor: 4.307

Review 4.  Mast cells in atopic dermatitis.

Authors:  Toshiaki Kawakami; Tomoaki Ando; Miho Kimura; Bridget S Wilson; Yuko Kawakami
Journal:  Curr Opin Immunol       Date:  2009-10-14       Impact factor: 7.486

5.  Dimerized Translationally Controlled Tumor Protein-Binding Peptide Ameliorates Atopic Dermatitis in NC/Nga Mice.

Authors:  Xing-Hai Jin; Juhyeon Lim; Dong Hae Shin; Jeehye Maeng; Kyunglim Lee
Journal:  Int J Mol Sci       Date:  2017-01-26       Impact factor: 5.923

6.  Beneficial effects of ROCEN (Topical Nano-arthrocen) on atopic dermatitis in mice.

Authors:  Ramin Goudarzi; Maryam Eskandarynasab; Ahad Muhammadnejad; Ahmad Reza Dehpour; Alireza Partoazar
Journal:  BMC Complement Med Ther       Date:  2021-09-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.